FDA Advisors Slam Lipocine’s Testosterone Pill, Raising Doubts About ‘Low T’ Drugs

Investors are fleeing from testosterone drugmaker Lipocine today, but its FDA woes portend bigger challenges for companies developing new versions of the embattled hormone.

This entry was posted in Articles. Bookmark the permalink.

Leave a Reply

Your email address will not be published.

*